1991
DOI: 10.1016/0006-2952(91)90108-h
|View full text |Cite
|
Sign up to set email alerts
|

Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
8
0

Year Published

1992
1992
2010
2010

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 38 publications
(9 citation statements)
references
References 23 publications
1
8
0
Order By: Relevance
“…Together, these observations strongly implicate a common enzyme, presumably DT-diaphorase (Tsuda et al, 1984), in the bioreduction of the two procarcinogens. In accord with this notion, the aerobic reduction of both 4NQO (Tsuda et al, 1984) and MMC (Keyes et al, 1989;Marshall et al, 1991b) has been demonstrated to be inhibited by dicumarol, a potent (although not specific) inhibitor of DT-diaphorase (Ernster, 1967). In our earlier work the level of DT-diaphorase activity was also determined for the five fibroblast strains in the polyposis/sarcoma family.…”
Section: Discussionsupporting
confidence: 49%
“…Together, these observations strongly implicate a common enzyme, presumably DT-diaphorase (Tsuda et al, 1984), in the bioreduction of the two procarcinogens. In accord with this notion, the aerobic reduction of both 4NQO (Tsuda et al, 1984) and MMC (Keyes et al, 1989;Marshall et al, 1991b) has been demonstrated to be inhibited by dicumarol, a potent (although not specific) inhibitor of DT-diaphorase (Ernster, 1967). In our earlier work the level of DT-diaphorase activity was also determined for the five fibroblast strains in the polyposis/sarcoma family.…”
Section: Discussionsupporting
confidence: 49%
“…Its unique structural properties and biological activity have motivated numerous studies to determine its cellular target sites and mechanism of action. Complete characterization of MMC (29,30) has been followed by studies examining the basis of its selectivity against mammalian tumor cells and the mechanisms that render mammalian tumor cells MMC resistant (5,14,18,22,26,27). However, the molecular basis for MMC resistance in the producing organism, S. lavendulae, has not been established.…”
mentioning
confidence: 99%
“…Mitomycin C is the prototype bioreductive agent which shows clinical activity against some solid tumours but exhibits little selectivity towards hypoxic tumour cells (Stratford and Stephens, 1989; Workman, 1992). It (Oostveen and Speckamp, 1987) is structurally related to mitomycin C (Fig. l), is less myelosuppressive (Hendriks et al, 1993) and is in clinical trial in Europe under the auspices of the EORTC.…”
mentioning
confidence: 97%